Patients struggling to break dependence on opioids will soon have a cheaper treatment option available following the US Food and Drug Administration’s (FDA) decision to approve the first generic sublingual version of Suboxone (buprenorphine and naloxone).  In April 2017, the US...

The US Food and Drug Administration (FDA) and Federal Trade Commission (FTC) have turned their attention to companies illegally marketing products to help with opioid withdrawal and addiction. The agencies sent letters to the marketers and distributors of the products with warnings about their...

In the latest step taken by the US Food and Drug Administration (FDA) to address the nation's opioid abuse epidemic, the agency has changed the indication of cough medicines containing opioids to exclude all pediatric patients.  Following the latest safety labeling changes, opioid cough and...

The US Food and Drug Administration has granted approval to Sublocade (buprenorphine extended release) for the treatment of patients with moderate to severe opioid use disorder. Shaun Thaxter, chief executive officer of Indivior, described the approval as an “important step forward for...

The 14th National Prescription Drug Take Back Day held on October 28th, 2017 has been hailed as the most successful yet, retrieving record quantities of unused medication. Run by the Drug Enforcement Agency (DEA), the events highlight the importance of proper disposal of unwanted drugs and provide...

The US Food and Drug Administration (FDA) is looking into improved packaging, storage and disposal strategies to address the opioid abuse epidemic in the United States. In a statement released at the end of October, FDA Commissioner Scott Gottlieb, MD, reaffirmed the regulatory body's...

Scott Gottlieb, MD, US Food and Drug Administration (FDA) Commissioner, has outlined the FDA's plans to tackle the nation's opioid abuse epidemic. Speaking to the House Committee on Energy and Commerce Hearing, he described opioid addiction as the "biggest crisis facing public health...

The US Food and Drug Administration (FDA) has announced a meeting with the Pediatric Advisory Committee to evaluate the use of prescription medication containing opioids when treating coughs in children. A statement by FDA Commissioner Scott Gottlieb, MD, highlighted the potential risks of these...

Endo International is reviewing a request from the US Food & Drug Administration (FDA) to remove the opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market. The government body's Drug Safety Risk Management and Anesthetic and Analgesic Drug Products...

Look through the drawers and cupboards of most households in the United States it’s likely you’ll find a blister pack or pill bottle with out-of-date or expired medication tucked away somewhere. So what should you do with these medicines? Are they safe to use, and if not, how should you...

A new formulation of the opioid oxycodone has been approved by the US Food & Drug Administration (FDA), providing doctors with a new option for treating patients in pain. RoxyBond (oxycodone hydrochloride) is the first immediate-release opioid analgesic with labeling for abuse-deterrent...

New restrictions on use of certain cough and pain medicine to treat children have been announced by the U.S. Food & Drug Administration (FDA). The government body warned parents and health care professionals that medicines containing codeine and tramadol carry "serious risks" to children under...